55,193 Shares in Cue Biopharma, Inc. $CUE Acquired by ADAR1 Capital Management LLC

Key Points

• ADAR1 Capital Management acquired 55,193 Cue Biopharma shares worth approximately $1.74 million, giving it a 1.31% stake. Institutional investors and hedge funds collectively own 35.04% of the company.
• Cue Biopharma reported a quarterly loss of $24.14 per share, significantly missing the $1.69 consensus estimate, although revenue of $7.88 million exceeded expectations.
• Analyst sentiment remains negative, with the stock receiving an average “Sell” rating. Shares opened at $26.76, while insiders sold 72,715 shares worth about $2.04 million during the last quarter.

ADAR1 Capital Management LLC acquired a new stake in shares of Cue Biopharma, Inc. (NASDAQ:CUE - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 55,193 shares of the company's stock, valued at approximately $1,742,000. ADAR1 Capital Management LLC owned approximately 1.31% of Cue Biopharma as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. increased its stake in shares of Cue Biopharma by 730.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company's stock worth $57,000 after acquiring an additional 73,000 shares during the last quarter. Squarepoint Ops LLC purchased a new position in Cue Biopharma in the third quarter valued at about $62,000. Boothbay Fund Management LLC purchased a new position in Cue Biopharma in the third quarter valued at about $439,000. GC Wealth Management RIA LLC increased its position in Cue Biopharma by 35.0% in the 4th quarter. GC Wealth Management RIA LLC now owns 4,631,644 shares of the company's stock worth $1,415,000 after purchasing an additional 1,200,000 shares during the last quarter. Finally, Texas Capital Bank Wealth Management Services Inc raised its stake in shares of Cue Biopharma by 1,231.2% during the 4th quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company's stock worth $135,000 after purchasing an additional 407,568 shares in the last quarter. Institutional investors and hedge funds own 35.04% of the company's stock.

Analyst Upgrades and Downgrades

CUE has been the subject of several recent research reports. Wall Street Zen downgraded shares of Cue Biopharma from a "hold" rating to a "sell" rating in a research report on Sunday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Cue Biopharma in a research note on Thursday, August 13th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of "Sell".

Cue Biopharma Stock Performance

NASDAQ:CUE opened at $26.76 on Wednesday. The firm's 50-day moving average is $29.29 and its 200-day moving average is $131.81. The company has a market cap of $194.28 million, a price-to-earnings ratio of -0.99 and a beta of 2.47. Cue Biopharma, Inc. has a 52-week low of $4.97 and a 52-week high of $45.50.

Cue Biopharma (NASDAQ:CUE - Get Free Report) last posted its quarterly earnings results on Friday, August 14th. The company reported ($24.14) earnings per share for the quarter, missing analysts' consensus estimates of ($1.69) by ($22.45). The business had revenue of $7.88 million for the quarter, compared to analyst estimates of $3.00 million. Cue Biopharma had a negative return on equity of 620.06% and a negative net margin of 435.83%.

Insiders Place Their Bets

In other Cue Biopharma news, insider Sumita Ray sold 8,829 shares of Cue Biopharma stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $30.09, for a total transaction of $265,664.61. Following the sale, the insider directly owned 118,545 shares of the company's stock, valued at approximately $3,567,019.05. The trade was a 6.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Shao-Lee Lin sold 40,000 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $27.10, for a total value of $1,084,000.00. Following the transaction, the chief executive officer owned 724,253 shares of the company's stock, valued at $19,627,256.30. This represents a 5.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 72,715 shares of company stock worth $2,041,555 over the last quarter. Company insiders own 14.56% of the company's stock.

About Cue Biopharma

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company's proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.

Want to see what other hedge funds are holding CUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cue Biopharma, Inc. (NASDAQ:CUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source